---
title: "Fosun International files HKEX next-day disclosure return reporting 13,027,000-share repurchase at HKD 3.7027 per share"
description: "Fosun International Limited has filed a next-day disclosure return with HKEX, reporting the repurchase of 13,027,000 ordinary shares at a volume-weighted average price of HKD 3.7027 per share. The tot"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277190284.md"
published_at: "2026-02-27T11:36:34.000Z"
---

# Fosun International files HKEX next-day disclosure return reporting 13,027,000-share repurchase at HKD 3.7027 per share

> Fosun International Limited has filed a next-day disclosure return with HKEX, reporting the repurchase of 13,027,000 ordinary shares at a volume-weighted average price of HKD 3.7027 per share. The total consideration for the repurchase amounted to HKD 48,235,385, with individual share prices ranging from HKD 3.63 to HKD 3.80. This disclosure was made on February 27, 2026.

Fosun International Limited filed a next day disclosure return with HKEX on 27 February 2026 reporting an on-market share repurchase. The company repurchased 13,027,000 ordinary shares on the Exchange, paying between HKD 3.63 and HKD 3.80 per share (volume-weighted average HKD 3.7027) for an aggregate consideration of HKD 48,235,385. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260227-12032584), on February 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [520880.CN - Hwabao WP Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520880.CN.md)
- [159506.CN - Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF](https://longbridge.com/en/quote/159506.CN.md)
- [02196.HK - FOSUN PHARMA](https://longbridge.com/en/quote/02196.HK.md)
- [600196.CN - FOSUN PHARMA](https://longbridge.com/en/quote/600196.CN.md)
- [08627.HK - ORANGE TOUR](https://longbridge.com/en/quote/08627.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Fosun Pharma Reports Strong Shareholder Turnout at 2026 Extraordinary Meetings | Shanghai Fosun Pharmaceutical (Group) Co. reported strong shareholder turnout at its 2026 extraordinary general meetings | [Link](https://longbridge.com/en/news/277222806.md) |
| Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | [Link](https://longbridge.com/en/news/276886600.md) |
| HKEX Sees Diverse IPOs Amid AI Bubble Risk | HKEX chief executive Bonnie Chan says the Hong Kong exchange has attracted a diverse range of IPO applicants, from diffe | [Link](https://longbridge.com/en/news/277069209.md) |
| HKEX Announces Second Interim Dividend of HK$6.52 Per Share for 2025 | Hong Kong Exchanges and Clearing Limited (HKEX) has declared a second interim dividend of HK$6.52 per share for the fina | [Link](https://longbridge.com/en/news/276993996.md) |
| Tikehau Capital: Disclosure of Shares Repurchases from 20 February 2026 to 26 February 2026 | Tikehau Capital has disclosed its shares repurchases from February 20 to February 26, 2026, in compliance with EU Regula | [Link](https://longbridge.com/en/news/277177004.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.